当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2017-11-03 , DOI: 10.1056/nejmoa1709846 Jennifer L. Taylor-Cousar , Anne Munck , Edward F. McKone , Cornelis K. van der Ent , Alexander Moeller , Christopher Simard , Linda T. Wang , Edward P. Ingenito , Charlotte McKee , Yimeng Lu , Julie Lekstrom-Himes , J. Stuart Elborn
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2017-11-03 , DOI: 10.1056/nejmoa1709846 Jennifer L. Taylor-Cousar , Anne Munck , Edward F. McKone , Cornelis K. van der Ent , Alexander Moeller , Christopher Simard , Linda T. Wang , Edward P. Ingenito , Charlotte McKee , Yimeng Lu , Julie Lekstrom-Himes , J. Stuart Elborn
|
The combination of tezacaftor and ivacaftor was efficacious and safe in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation. (Funded by Vertex Pharmaceuticals; EVOLVE ClinicalTrials.gov number, NCT02347657.)
中文翻译：
Tezacaftor–Ivacaftor用于Phe508del的囊性纤维化纯合患者
tezacaftor和ivacaftor的联合治疗对12岁或12岁以上患有囊性纤维化且对CFTR Phe508del突变纯合的患者有效且安全。（由Vertex Pharmaceuticals资助； EVOLVE ClinicalTrials.gov编号，NCT02347657。）
更新日期：2017-11-23
中文翻译：
Tezacaftor–Ivacaftor用于Phe508del的囊性纤维化纯合患者
tezacaftor和ivacaftor的联合治疗对12岁或12岁以上患有囊性纤维化且对CFTR Phe508del突变纯合的患者有效且安全。（由Vertex Pharmaceuticals资助； EVOLVE ClinicalTrials.gov编号，NCT02347657。）
京公网安备 11010802027423号